X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

NHS To Offer Variant-Busting Booster Before The Winters

Content Team by Content Team
24th August 2022
in News, Research & Development
NHS To Offer Variant-Busting Booster Before The Winters

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The NHS has now laid out plans for the next stage of the COVID-19 vaccination effort, the biggest and most rapid vaccine drive in the history of the health service, in response to the updated guidelines outlined by the JCVI.

Staff from the NHS will start immunising those who are homebound and those who stay in nursing homes in the week of September 5.

The NHS is encouraging those who are most at risk of serious illness from COVID-19 and those who are 75 years of age and older to book an appointment starting that week. The National Booking Service will also launch that week ahead of the wider rollout, which is scheduled to begin on September 12.

In order to ensure that inhabitants of senior care homes can receive protection as soon as possible, local areas have already scheduled adult care home residents for their vaccination.

People can make appointments online or through 119 as long as it has been three months since their last dose. As with previous campaigns, the elderly and most vulnerable will be called forward first. To make obtaining the additional protection as simple as possible, the NHS will continue to urge local sites to permit immunocompromised patients to self-declare and attend walk-ins.

According to the JCVI’s recommendations, about 26 million people in England will be eligible for an autumn booster.

The launch is anticipated to include up to 3,000 venues, including GP practises and neighbourhood pharmacies, and more sites are constantly joining the initiative.

The NHS is taking a number of steps to get ready for winter, including boosting bed capacity and staffing NHS 111 and 999 to handle any unforeseen load. The autumn booster programme is one of these steps.

Since the first COVID-19 vaccine was administered outside of clinical studies to Maggie Keenan in Coventry in December 2020, more than 126 million COVID vaccinations have been given by NHS personnel and volunteers.

The NHS urged those who were eligible to receive a spring booster dose before the end of July in order to ensure that enough time has elapsed to maximise the safeguards an autumn booster might provide over the winter. Well over four out of five eligible people did receive a spring booster earlier this year.

The NHS will be the first healthcare system in the world to administer the new, variant-busting vaccination when the rollout starts at the beginning of September, according to Amanda Pritchard, chief executive of the NHS. The NHS was the first care system in the world to provide a COIVD-19 vaccine outside of clinical trials.

Their amazing NHS staff have worked incredibly hard to deliver 126 million doses to date, and they have again been working behind the scenes to prepare to deliver the newest process with the same speed and accuracy as they have had throughout the rollout.

When the time comes, she would strongly advise anyone who has been welcomed to take both an autumn booster and a flu shot to do so as quickly as possible. It will give them the best protection this winter.

Where appropriate and provided that there is a sufficient supply made available to the NHS, the new next-generation bivalent vaccine will be made available to the public. The JCVI and MHRA have emphasised that regardless of the vaccine offered, people need to come forward and that the original immunizations continue to offer excellent protection. According to Steve Russell, director of vaccinations and screening for the NHS, “This winter will be the first time they really see the effects of both COVID and flu in full circulation as they go about their lives as usual, and it is essential that those most vulnerable to severe disease from these viruses come forward for the latest shot in order to protect themselves.”

It is excellent that so many have chosen to participate in the most recent phase of the campaign. They know that the GPs and community pharmacists have been important to the achievement of the NHS Vaccination Programme due to their placements and partnerships with various local communities.

The NHS will get in touch with people when it is their turn to receive an autumn booster and will invite the first people living outside of a care facility to schedule an appointment before the official rollout in early September. When contacted, she insists on scheduling an appointment as soon as possible to ensure their protection this winter.

One does not need to approach the NHS; when it is their turn to schedule the vaccination, the NHS will call.

The flu vaccine will also be distributed by the NHS, and eligible individuals are urged to take advantage of the deal as soon as possible, beginning on the first of the month. The flu shot and COVID vaccination may be given to eligible people simultaneously if the doses are okayed for co-administration. Local systems will distribute the flu shot in a method that suits them best.

In accordance with JCVI recommendations, employees in the health and social care sectors will also be eligible for the autumn booster. To ensure the safety of NHS employees, all providers are urged to make sure their staff members are offered the autumn vaccine and, whenever possible, co-administer it with the flu shot.

Previous Post

Evidence Shows Alzheimer Benefits From Genuv Cancer Drug

Next Post

US Gives Lynparza Priority Review If Paired With Abiraterone

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

US Gives Lynparza Priority Review If Paired With Abiraterone

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In